CAPTOR THERAPEUTICS SPOLKA AKCYJNA

Press Releases Captor Therapeutics Spolka Akcyjna

Equities

CTX

PLCPTRT00014

Market Closed - Warsaw S.E. Other stock markets 16:55:48 15/05/2024 BST			5-day change	1st Jan Change
77.2 ^PLN	0.00%		-2.77%	-22.02%

2023	Captor Therapeutics Spolka Akcyjna Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	Captor Therapeutics Spolka Akcyjna Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Captor Therapeutics Publishes Q1 2023 Financial Results	30/05/23	AQ
Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast	28/03/23	AQ
Captor Therapeutics Announces Three-Year Strategic Objectives	07/03/23	AQ
Captor Therapeutics Reports Q3 2022 Results and Provides Business UpdateLead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical	28/11/22	AQ
Captor Therapeutics Reports Q3 2022 Results and Provides Business Update	25/11/22	AQ
Ono Enters a Drug Discovery Collaboration Agreement with Captor Therapeutics to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases	15/11/22	AQ
Ono Pharmaceutical and Captor Therapeutics Announce Drug Discovery Collaboration to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases	14/11/22	AQ
Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma	10/08/22	AQ
Captor Therapeutics to Host R&D Day on May 18, 2022	05/05/22	GL
Captor Therapeutics to Host R&D Day on May 18, 2022	05/05/22	AQ
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma	12/04/22	AQ
Captor Therapeutics Invited to TPD Panel at the 8th Annual LSX World Congress 2022	11/04/22	GL
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma	13/01/22	GL
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma	13/01/22	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer